
    
      1. Phase II/III study,

        2. Randomized, multicenter, open-label study,

        3. Evaluated the effects of chemotherapy combination with autologous cytokine-induced
           killer Cell immunotherapy compared with chemotherapy in patients with stage IIIb-IV
           squamous non-small-cell lung cancer
    
  